Woman stabbed to death for resisting snatching bid in Delhi; 10 police teams to probe case
Moderna, DPH say vaccine "stable and good to use" despite freezer issue at Hartford health clinic
The Family of Allen Willman
Editorial: Lawmakers’ plates are filled with weighty issues; it’s time to be sure they do no harm
Paducah restaurants remain hopeful for business after COVID-19
Renamed Tumwater Middle School honors Chinuk Wawa language
Project Director jobs in Islamabad at Federal Employees Benevolent & Group Insurance Funds on February 28,2021
Levy on property should replace ‘unfit and outdated’ council tax, Scots think tank says
Lack of constitution-building has greatly damaged independence movement
Rare Disease Day: The family who lost three children
Taoiseach slams anti-lockdown demonstrators’ ‘thuggish’ acts on Irish police
One-and-done Covid vaccine could be just weeks away after jab gets cleared by US
Lower Your Risk Of Heart Disease By Following The ABC’s
WKU student starts 'micro pantry' program in city
Social media companies with 50 lakh users to be accountable under new IT rules
Anger grows over UK Government's four-year failure on abuse of women
What following of the data?
The Mystery Of The Covid Deaths Taking Months To Appear In NHS Data
Kobe Bryant's widow blasts 'vile' Evan Rachel Wood for branding sportsman a 'rapist'
On ‘S.N.L.,’ Dr. Fauci Hosts ‘So You Think You Can Get the Vaccine’
Netflix to develop 'Terminator' anime series
BioNano Genomics Inc may provide buying opportunity with a potential Wednesday dip

Update February 17: BioNano Genomics (NASDAQ: BNGO) has closed Tuesday's trading session at $15.Coronavirus mutations have raised awareness of genetic sequencing and BioNano Genomics (NASDAQ: BNGO) is well-placed to benefit from this growing need.NASDAQ: BNGO has closed Friday's trading on a high note – a leap of $2 or 17.Coronavirus: Statistics, herd immunity, vaccine calendar and impact on financial markets and currencies BioNano Genomics' latest announcements came from its conference, where it presented the capabilities of its Spahyr tools – impressing medics.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.FXStreet and the author do not provide personalized recommendations.